MA53706A - Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne - Google Patents
Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienneInfo
- Publication number
- MA53706A MA53706A MA053706A MA53706A MA53706A MA 53706 A MA53706 A MA 53706A MA 053706 A MA053706 A MA 053706A MA 53706 A MA53706 A MA 53706A MA 53706 A MA53706 A MA 53706A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- bacterial infection
- indane derivatives
- indane
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18290106.6A EP3628666A1 (fr) | 2018-09-25 | 2018-09-25 | Dérivés d'indane pour le traitement des infections bactériennes |
| EP18290104 | 2018-09-26 | ||
| EP18197365 | 2018-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53706A true MA53706A (fr) | 2021-12-29 |
Family
ID=67439236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053707A MA53707A (fr) | 2018-09-25 | 2019-07-25 | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne |
| MA053706A MA53706A (fr) | 2018-09-25 | 2019-07-25 | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053707A MA53707A (fr) | 2018-09-25 | 2019-07-25 | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12247013B2 (fr) |
| EP (2) | EP3856729A1 (fr) |
| JP (2) | JP7429992B2 (fr) |
| KR (2) | KR102833669B1 (fr) |
| CN (2) | CN113166085B (fr) |
| AU (2) | AU2019349438B2 (fr) |
| BR (2) | BR112021005651A2 (fr) |
| CA (2) | CA3113697A1 (fr) |
| CL (2) | CL2021000731A1 (fr) |
| IL (2) | IL281770B2 (fr) |
| MA (2) | MA53707A (fr) |
| MX (2) | MX2021003485A (fr) |
| SG (2) | SG11202102790PA (fr) |
| WO (2) | WO2020064174A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53707A (fr) | 2018-09-25 | 2021-12-29 | Antabio Sas | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne |
| US20240016941A1 (en) * | 2020-03-24 | 2024-01-18 | Antabio Sas | Combination therapy |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR81744B (fr) | 1983-01-28 | 1984-12-12 | Schering Corp | |
| US5457196A (en) * | 1991-09-27 | 1995-10-10 | Merrell Dow Pharmaceuticals Inc. | 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
| JP3126541B2 (ja) * | 1993-03-26 | 2001-01-22 | 千寿製薬株式会社 | ベンゾチアゾール誘導体、その製法及びその用途 |
| JPH0782259A (ja) | 1993-09-14 | 1995-03-28 | Senju Pharmaceut Co Ltd | スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤 |
| DE4339198A1 (de) | 1993-11-16 | 1995-05-18 | Max Planck Gesellschaft | Verwendung bestimmter aromatischer Derivate als Fungizide und/oder Antibiotika |
| US6514996B2 (en) | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
| CN1226175A (zh) | 1996-07-23 | 1999-08-18 | 第一制药株式会社 | 吸收促进剂 |
| JPH11130761A (ja) | 1997-10-24 | 1999-05-18 | Otsuka Pharmaceut Co Ltd | ベンゾチアゾール誘導体 |
| AR036237A1 (es) | 2001-07-27 | 2004-08-25 | Bayer Corp | Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento |
| UA79755C2 (en) | 2002-04-16 | 2007-07-25 | Bayer Pharmaceuticals Corp | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| WO2003094889A1 (fr) | 2002-05-13 | 2003-11-20 | Daiichi Pharmaceutical Co., Ltd. | Produit de lyophilisation |
| PA8597401A1 (es) | 2003-03-14 | 2005-05-24 | Pfizer | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep |
| US20050070543A1 (en) | 2003-07-11 | 2005-03-31 | Pharmacia Corporation | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage |
| CN101014602B (zh) | 2004-09-08 | 2011-08-10 | 默沙东公司 | 单环酰苯胺螺环内酰胺cgrp受体拮抗剂 |
| FR2883876B1 (fr) | 2005-03-30 | 2007-05-04 | Servier Lab | Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2608091A1 (fr) | 2005-05-11 | 2006-11-16 | Abbott Laboratories | Antagonistes du recepteur (vr1) du sous-type 1 du recepteur de vanilloide et utilisations afferentes |
| WO2006125511A1 (fr) | 2005-05-25 | 2006-11-30 | Merck Patent Gmbh | Derives de pyrane-dioxane et utilisation de ceux-ci dans des milieux a cristaux liquides |
| WO2007031860A1 (fr) | 2005-09-15 | 2007-03-22 | Pfizer Japan Inc. | Benzimidazoles substitués par un indane et leur emploi en tant qu’inhibiteurs de la pompe à acide |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| WO2007099423A1 (fr) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3 |
| WO2008036967A2 (fr) | 2006-09-22 | 2008-03-27 | Reddy Us Therapeutics, Inc. | Nouveaux composes heterocycliques utilises en tant qu'activateurs de la synthase d'acide lipoique |
| CN101679346B (zh) | 2007-06-05 | 2014-10-22 | 塞诺菲-安万特股份有限公司 | 取代的苯甲酰氨基茚满-2-羧酸及相关化合物 |
| EP2141164A1 (fr) | 2008-07-01 | 2010-01-06 | Mutabilis | Nouveaux dérivés 1,2,4-triazine et leurs applications biologiques |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| AU2012222874B2 (en) | 2011-03-02 | 2015-04-16 | Bionomics Limited | Novel small-molecules as therapeutics |
| UA117820C2 (uk) * | 2012-11-30 | 2018-10-10 | Байєр Кропсайєнс Акцієнгезелльшафт | Подвійна фунгіцидна або пестицидна суміш |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| GB201704476D0 (en) * | 2017-03-21 | 2017-05-03 | Antabio Sas | Chemical compounds |
| SG11202009245TA (en) | 2018-03-21 | 2020-10-29 | Relay Therapeutics Inc | Shp2 phosphatase inhibitors and methods of use thereof |
| MA53707A (fr) | 2018-09-25 | 2021-12-29 | Antabio Sas | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne |
| EP3856195A4 (fr) | 2018-09-26 | 2022-06-22 | Alkahest, Inc. | Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3 |
| MX2021003530A (es) | 2018-09-27 | 2021-05-27 | Fmc Corp | Herbicidas de piridazinona e intermediarios de piridazinona usados para preparar un herbicida. |
-
2019
- 2019-07-25 MA MA053707A patent/MA53707A/fr unknown
- 2019-07-25 MX MX2021003485A patent/MX2021003485A/es unknown
- 2019-07-25 JP JP2021540369A patent/JP7429992B2/ja active Active
- 2019-07-25 WO PCT/EP2019/070116 patent/WO2020064174A1/fr not_active Ceased
- 2019-07-25 KR KR1020217012348A patent/KR102833669B1/ko active Active
- 2019-07-25 CN CN201980066561.2A patent/CN113166085B/zh active Active
- 2019-07-25 KR KR1020217012349A patent/KR102833646B1/ko active Active
- 2019-07-25 CA CA3113697A patent/CA3113697A1/fr active Pending
- 2019-07-25 US US17/277,535 patent/US12247013B2/en active Active
- 2019-07-25 AU AU2019349438A patent/AU2019349438B2/en active Active
- 2019-07-25 WO PCT/EP2019/070115 patent/WO2020064173A1/fr not_active Ceased
- 2019-07-25 BR BR112021005651-3A patent/BR112021005651A2/pt unknown
- 2019-07-25 MA MA053706A patent/MA53706A/fr unknown
- 2019-07-25 EP EP19744709.7A patent/EP3856729A1/fr active Pending
- 2019-07-25 IL IL281770A patent/IL281770B2/en unknown
- 2019-07-25 MX MX2021003498A patent/MX2021003498A/es unknown
- 2019-07-25 BR BR112021005532-0A patent/BR112021005532A2/pt unknown
- 2019-07-25 JP JP2021540370A patent/JP7429993B2/ja active Active
- 2019-07-25 EP EP19744710.5A patent/EP3856730A1/fr active Pending
- 2019-07-25 CN CN201980063308.1A patent/CN113166084B/zh active Active
- 2019-07-25 AU AU2019351551A patent/AU2019351551B2/en active Active
- 2019-07-25 SG SG11202102790PA patent/SG11202102790PA/en unknown
- 2019-07-25 SG SG11202102791SA patent/SG11202102791SA/en unknown
- 2019-07-25 US US17/277,649 patent/US12286411B2/en active Active
- 2019-07-25 CA CA3113689A patent/CA3113689A1/fr active Pending
-
2021
- 2021-03-24 CL CL2021000731A patent/CL2021000731A1/es unknown
- 2021-03-24 CL CL2021000729A patent/CL2021000729A1/es unknown
- 2021-03-24 IL IL281780A patent/IL281780B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| EP3405183A4 (fr) | Dérivés d'adamatane pour le traitement d'une infection à filovirus | |
| MA49760A (fr) | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| MA50800A (fr) | Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson | |
| EP3572050A4 (fr) | Agent de traitement d'excréments destiné à être utilisé dans des colostomies | |
| EP3374350A4 (fr) | Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| MA40221A (fr) | Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale | |
| MA55821A (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| EP3890749A4 (fr) | Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer | |
| EP3641746A4 (fr) | Méthodes et compositions pour le traitement d'une infection microbienne | |
| EP3846821A4 (fr) | Polythérapie destinée au traitement d'une maladie hépatique | |
| MA50233A (fr) | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité | |
| EP4069700A4 (fr) | Macrocycles destinés à être utilisés dans le traitement d'une maladie | |
| MA43861A (fr) | Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie | |
| EP3645120A4 (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression | |
| EP3654961A4 (fr) | Méthodes et compositions pour le traitement de la douleur à l'aide de la capsaïcine | |
| EP4149481A4 (fr) | Thiosaccharides destinés à être utilisés dans le traitement d'une infection à coronavirus | |
| MA54512A (fr) | Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer | |
| EP3768274A4 (fr) | Composition destinée à être utilisée dans le traitement d'états provoqués par une déficience en calcium | |
| EP3592349A4 (fr) | Administration de composés antibiotiques pour le traitement d'infections streptococciques, pour le traitement du psoriasis | |
| MA53706A (fr) | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne | |
| EP3856213A4 (fr) | Procédés de traitement d'infections à l'aide de bactéries | |
| EP3840729A4 (fr) | Traitement d'une lésion médullaire et d'une lésion cérébrale à l'aide de gsx1 |